Skip to content

Effects of Diffused Ylang-Ylang Essential Oil Amongst Older Persons With Dementia

Effects of Diffused Ylang-Ylang (Cananga Odorata) Essential Oil Amongst Older Persons With Dementia: A Pre-Post Quasi-Experimental Study Protocol

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05034107
Enrollment
28
Registered
2021-09-05
Start date
2021-06-30
Completion date
2022-06-02
Last updated
2022-11-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Behavioral and Psychiatric Symptoms of Dementia, Dementia

Keywords

Aromatherapy, Ylang-Ylang, Behavioral and Psychological Symptoms of Dementia, Dementia

Brief summary

Ylang-Ylang (Cananga Odorata) essential oil has been postulated to have calming effect, which may improve BPSD in persons with dementia. This study aims to examine dementia-related behavioural changes using established assessment tools and brain derived neurotropic factor (BDNF) in persons with BPSD.

Detailed description

Behavioural and Psychological Symptoms of Dementia (BPSD) refers to the spectrum of non-cognitive and non-neurological symptoms of dementia, such as agitation, psychosis, depression and apathy. Ylang-Ylang (Cananga Odorata) essential oil is postulated to have calming effect, which may improve BPSD in persons with dementia. Thus, this study aims to examine dementia-related behavioural changes using established assessment tools and brain derived neurotropic factor (BDNF) in persons with BPSD. A pre-post quasi-experimental pilot study will be conducted over a two-month period in nursing homes with persons with dementia. Approximately 30 persons with dementia are expected to participate in this study. During the pre-intervention phase, water will be diffused using a diffuser in a common area of the nursing homes. During the intervention phase, Ylang-Ylang essential oil will be diffused using the identical diffuser over the same common area. Both water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases. Observation and documentation of behavioural symptoms will be taken using validated instruments during the pre- and post-intervention phases. In addition, 10 mL of blood will also be collected at pre and post intervention for biochemical analyses.If Ylang-ylang essential oil were found to be beneficial based on the laboratory and observational findings, it can be possibly used as an alternative approach in managing BPSD.

Interventions

OTHERAromatherapy

Approximately 6-7 drops of Ylang-ylang essential oil will be diffused in a common area estimated to be about 300 square feet with temperature of around 25 - 26 degree Celsius and humidity of 50% - 60%. Water and essential oil will be diffused twice a day, each for a duration of 20 min during the respective phases.

Sponsors

Universiti Sains Malaysia
CollaboratorOTHER
University of Malaya
CollaboratorOTHER
Universiti Teknologi Mara
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
SUPPORTIVE_CARE
Masking
NONE

Intervention model description

A pre-post quasi-experimental study will be conducted over a two-month period in nursing homes with persons with dementia. During the pre-intervention phase, essential oil diffusers containing water will be diffused in the common area of the nursing homes. During the intervention phase, Ylang-Ylang essential oil will be diffused using an identical diffuser. Behavioural parameters and blood samples will be taken after pre and post intervention phase.

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Persons who have been diagnosed with dementia by their physicians and in nursing homes in Selangor, Malaysia. * Persons with dementia who have at least one symptom of BPSD

Exclusion criteria

* Persons with dementia with a comorbid respiratory problem like asthma or chronic obstructive pulmonary disease * Persons with dementia who are allergic to fragrance/perfumes * Persons with dementia who had a change in their psychotropic or dementia medications in the 30 days before commencement of the study, namely: acetylcholinesterase inhibitors N-methyl-D-aspartate (NMDA)-receptor antagonist (memantine), antipsychotics, antidepressants, sedatives, or medications with anticholinergic properties * Persons who have been diagnosed with schizophrenia or mental retardation * Persons who have no documented behavioral history in the previous three month * Persons who are currently hospitalized * Persons with dementia who are unwilling to participate or disallowed by caregivers/family members

Design outcomes

Primary

MeasureTime frameDescription
Cornell Scale for Depression in Dementia2 monthsThe mean counts of this parameter before and after intervention phase will be analysed using Cornell Scale for Depression in Dementia. The score more than 18 means the persons is having definite major depressive episode.
Cohen-Mansfield Agitation Inventory2 monthsThe mean counts of this parameter before and after the intervention phase will be analysed using Cohen-Mansfield Agitation Inventory. A rating of five indicates that the person is having frequent agitation within an hour.
Neuropsychiatric Inventory- Brief Questionnaire Form2 monthsThe mean counts of this parameter before and after the intervention phase will be analysed using the Neuropsychiatric Inventory- Brief Questionnaire Form. A person is undergoing severe symptoms of BPSD if the score is 3, while caregivers are undergoing more distress when the score is 5.

Secondary

MeasureTime frameDescription
cytokines (150μL )2 monthsIL-2, IL-6, IL-8, and TNF-α levels will be tested using Plex Proteomic Assay kit.
Cortisol( 50μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.
adrenocorticotropic hormone (50μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.
Serum BDNF (100μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.
Reduced Glutathione (GSH) (0.7 mL)2 monthsColorimetric Assay Kit will be used.
Thiobarbituric Acid Reactants (TBARS) (0.1mL)2 monthsColorimetric Assay Kit will be used.
Total Antioxidant Capacity (T-AOC) (10 μL)2 monthsColorimetric Assay Kit will be used.
MDA(Malondialdehyde) (50μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.
Amyloid Beta (Aβ1-40) (100μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.
Amyloid Beta (Aβ1-42) (100μL)2 monthsEnzyme linked immunosorbent assay (ELISA) will be used.

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026